A probiotic composition for relieving constipation and its application

Through the combination of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 and wheat peptide, a probiotic composition that significantly relieves constipation was formed, solving the existing differences in probiotic effects The lack of combination schemes with multiple bacteria has achieved effective prevention and treatment of constipation.

CN116121136BActive Publication Date: 2024-11-15HANGZHOU KANGYUAN FOOD SCI & TECH

Patent Information

Application Number
CN202211722201.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-30
Publication Date
2024-11-15
Estimated Expiration
2042-12-30

AI Technical Summary

Technical Problem

The existing probiotics have great differences in the effects of relieving constipation, and the different bacterial species have different targets for constipation symptoms. There is a lack of effective combination of multiple bacterial strains to achieve significant clinical symptoms relief.

Method used

The combination of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 was used to combine wheat peptides and form a probiotic composition to synergize and significantly alleviate the symptoms of constipation.

Benefits of technology

The probiotic composition significantly relieves constipation to normal levels, has the characteristics of comprehensive effects, significant functions and durability, and can significantly promote intestinal peristalsis and improve intestinal health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116121136B_ABST
    Figure CN116121136B_ABST
Patent Text Reader

Abstract

The present invention discloses a probiotic composition for relieving constipation and its application, belonging to the field of microbial technology. The probiotic composition includes a probiotic combination, and the probiotic combination includes: Lactobacillus plantarum ZJUF SYS1 with a preservation number of CCTCC NO: M 2022662, Lactobacillus plantarum ZJUF T34 with a preservation number of CCTCC NO: M 2017399, and Lactobacillus rhamnosus ZJUF W1 with a preservation number of CCTCC NO: M2017398. The colony count ratio of each species in the composition is 1-10: 1-10: 1-10. The three species work synergistically to effectively relieve the symptoms of constipation, and have a good preventive and therapeutic effect on constipation. Furthermore, the present invention compounds wheat peptides on this basis, and this combination produces a synergistic effect, significantly relieves constipation to a normal level, and provides a comprehensive, functional and lasting solution for constipation treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a probiotic composition for relieving constipation and an application thereof. Background Art

[0002] Constipation is a symptom of many diseases and can also be used as a diagnosis of an independent disease. Common symptoms of constipation are a significant decrease in the number of bowel movements, less than 3 bowel movements per week, dry and hard stools, and pathological phenomena such as difficulty in defecation (including labored defecation, difficulty in defecation, a feeling of incomplete defecation, time-consuming defecation, and the need for manual defecation). Although the harm of constipation itself seems to be small, constipation may cause physical discomfort such as abdominal distension, vomiting, intestinal obstruction and perforation, increase the risk of anxiety and irritability, reduce appetite, thereby affecting the individual's quality of life and causing varying degrees of psychological disorders. Long-term constipation may also increase the risk of many related diseases such as kidney disease, Parkinson's disease and colorectal cancer.

[0003] There are many main clinical drugs for the treatment of constipation, including osmotic laxatives (lactulose and polyethylene glycol, etc.), stimulant laxatives (bischlorobiphenyl and senna, etc.), and stool softeners (mineral oil, etc.). However, drug treatment has problems such as inconsistent efficacy, repeated attacks, drug safety, adverse reactions, poor patient adaptability, and easy drug dependence. A large number of studies have shown that supplementing with probiotics can relieve constipation symptoms, which is also one of the commonly used methods for relieving constipation in clinical practice.

[0004] In recent years, many studies have shown that intestinal flora plays an important role in the occurrence and development of constipation. Probiotics are a type of active microorganisms that work by improving the balance of the host's intestinal microbial flora. They have important physiological functions such as improving the structure of intestinal flora, promoting the proliferation of beneficial bacteria in the intestine, inhibiting the growth of harmful bacteria, enhancing immunity, and improving intestinal barriers. At present, there are three main types of bacteria used to relieve constipation: Bifidobacteria, such as Bifidobacterium longum and Bifidobacterium breve; lactic acid bacteria, such as Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, and Lactobacillus bulgaricus; enterococci, such as Enterococcus faecalis and Enterococcus Faecium.

[0005] According to existing reports, probiotics can improve patients' constipation symptoms, but the effects of each study vary greatly, and there are also great differences between different strains. The reason for the differences in the effects of these probiotics on constipation symptoms may be due to the characteristics of the probiotics themselves. Although some health-related mechanisms of action are common in multiple probiotic genera and species, some functions are species-specific or even strain-specific, or may require interactions between different strains to produce effects. On the other hand, there are many causes of constipation, including the intestinal environment, nervous system, intestinal barrier and intestinal microbial homeostasis, and different probiotics have different targets for improving constipation. Although it may be expected that high-dose combinations of multiple probiotic strains may increase beneficial bacterial populations, improve microbial diversity and reduce dysbiosis, scientific evidence on microbial diversity shifts associated with constipation symptom improvement is still lacking. There will be antagonism between different microorganisms, and probiotic strain combinations may not necessarily be better or more effective than single strains in achieving the desired effect of clinical symptom relief goals. The clinically effective amount is obtained through experiments and may occur based on the synergistic combination of certain amounts of multiple bacterial strains.

[0006] In recent years, a large number of studies have shown that probiotics combined with compound glutamine have a significant effect on improving intestinal health. Glutamine can protect the intestinal mucosa and promote the recovery of intestinal function. In our study, we found that wheat peptides are rich in glutamine. Our previous study also found that wheat peptides with the same glutamine content have a stronger effect on promoting intestinal peristalsis than glutamine. Wheat peptides can improve loperamide hydrochloride-induced constipation in mice by maintaining intestinal motility and health. At present, there is a lack of sufficient understanding and research on the relationship between probiotics combined with wheat peptides and the immune, gastrointestinal nervous system, intestinal flora and its metabolites and constipation. In our previous studies, we found that some strains will even offset the function of wheat peptides in promoting intestinal peristalsis, and the mechanism is unclear.

[0007] Therefore, it is a technical problem that those skilled in the art need to solve to find different types of microorganisms and / or their compositions that relieve constipation and combine them with bioactive peptides to provide a comprehensive, functional and long-lasting constipation solution for the field of constipation treatment. Summary of the invention

[0008] The purpose of the present invention is to overcome the problem in the prior art that the effects of probiotics on improving constipation vary greatly, provide a probiotic composition that can effectively relieve constipation, and apply the probiotic composition to products that relieve constipation.

[0009] To achieve the above object, the present invention adopts the following technical solutions:

[0010] The invention provides a probiotic composition for relieving constipation. The probiotic composition comprises a probiotic combination, wherein the probiotic combination comprises: Lactobacillus plantarum ZJUF SYS1 with a preservation number of CCTCC NO: M 2022662, Lactobacillus plantarum ZJUF T34 with a preservation number of CCTCC NO: M 2017399 and Lactobacillus rhamnosus ZJUF W1 with a preservation number of CCTCC NO: M 2017398, wherein the colony count ratio of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 in the composition is 1-10:1-10:1-10.

[0011] The present invention screens and compound probiotics that have the effect of relieving constipation, and finds that the combination of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 has a significant effect on relieving constipation, and the effective dose is lower than that of a single probiotic, indicating that the above strain combination has a synergistic effect on relieving constipation.

[0012] Preferably, the colony count per unit mass of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 in the composition is 1×10 5 CFU~1×10 12 CFU CFU / g.

[0013] Preferably, the colony count ratio of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 in the composition is 1:1:1.

[0014] More preferably, the colony count of each strain in the composition reaches 1×10 10 CFU~1×10 12 CFU.

[0015] Furthermore, the probiotic composition also includes auxiliary ingredients, and the auxiliary ingredients include wheat peptides.

[0016] The present invention intervenes in the constipation mouse model by combining the above-mentioned probiotic combination with wheat peptides. The results show that the combination of the probiotic combination and wheat peptides can significantly relieve constipation to a normal level.

[0017] The wheat peptide is a glutenin hydrolysate. Preferably, the hydrolysis degree of the wheat peptide is 5.0-8.0%, wherein the peptide with a relative molecular weight less than 1000Da accounts for 45-60%.

[0018] Preferably, the ratio of the probiotic combination to the auxiliary ingredients in the composition is 1×10 5 CFU~1×10 12CFU: 1~6g.

[0019] More preferably, the ratio of the probiotic combination to the wheat peptide in the composition is 1×10 10 CFU~1×10 12 CFU: 1~6g.

[0020] The present invention also provides the use of the probiotic composition in preparing a medicine for treating or assisting in treating constipation or a food for alleviating constipation.

[0021] The probiotic composition provided by the present invention can be used to prepare a pharmaceutical composition, which contains a pharmaceutically effective dose of live bacteria of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1. In addition, the pharmaceutical composition may also contain a suitable pharmaceutical carrier. The pharmaceutical dosage form may be in the form of capsules, tablets, granules, powders or sustained-release agents. The pharmaceutical composition of the present invention can be used to prevent and treat constipation-related diseases.

[0022] The probiotic composition provided by the present invention can also be prepared into food, health products and the like to prevent and treat constipation and improve the health of users. The food and health products can be in the form of liquid beverages, solid beverages, oral liquids, dairy products, tablets, soft candies or capsules.

[0023] Furthermore, the constipation is functional constipation.

[0024] Furthermore, the effective doses of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 in the medicine or food are all 10 10 CFU~10 12 CFU / day.

[0025] The present invention has the following beneficial effects:

[0026] (1) The present invention obtains a probiotic combination of Lactobacillus plantarum ZJUFSYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 by screening and compounding multiple probiotics. The three strains work synergistically to effectively relieve constipation symptoms and have a good preventive and therapeutic effect on constipation. The present invention provides a comprehensive, functional and long-lasting solution for constipation treatment.

[0027] (2) The present invention is based on the combination of three strains of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUFW1, and wheat peptide is compounded. This combination produces a synergistic effect and can significantly relieve constipation to a normal level. Moreover, the combination has the characteristics of good water solubility, easy absorption, good taste, fast onset, and good physical feeling (relaxed, carefree, clean, and comfortable). BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 It is the time of the first black stool of the mice in Example 1.

[0029] Figure 2 It is the number of fecal particles excreted by the mice in Example 1 within 5 hours.

[0030] Figure 3 It is the moisture content of mouse feces in Example 1.

[0031] Figure 4 It is the time of the first black stool of the mice in Example 2.

[0032] Figure 5 It is the number of fecal particles excreted by the mice in Example 2 within 5 hours.

[0033] Figure 6 It is the moisture content of mouse feces in Example 2.

[0034] Figure 7 It is the first intestinal peristalsis peak time of zebrafish in Example 3.

[0035] Note: The above experimental data were statistically analyzed using GraphPad Prism 6.0 software, and the data were expressed as mean ± standard error. The differences between multiple groups were compared using Tukey's test in the Two-way ANOVA test for variance analysis and significance analysis. p<0.05 was considered to be statistically significant.

[0036] The * mark indicates a significant difference compared with the CON group; ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.0001; the # mark indicates a significant difference compared with the LOP group: ### indicates p<0.001, and #### indicates p<0.0001. DETAILED DESCRIPTION

[0037] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.

[0038] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0039] In the above embodiments, Lactobacillus plantarum T34, Lactobacillus plantarum SYS1, and Lactobacillus rhamnosus W1 are all deposited in China Center for Type Culture Collection (address: Wuhan University, Wuhan, China).

[0040] Specifically, Lactobacillus plantarum ZJUF T34 was deposited in China Center for Type Culture Collection (address: Wuhan University, Wuhan, China) on June 29, 2017, with a deposit number of CCTCC NO: M2017399, see Chinese patent application number 201711405499.4.

[0041] Screening, isolation and identification of Lactobacillus plantarum ZJUF SYS1: 5 g Sichuan pickled vegetables were added to 45 mL 0.85% sterile saline and shaken well. The mixture was diluted to 10% with saline. -5 , 10 -6 , 10 -7 , respectively, spread on MRS medium, and make 3 parallels for each gradient. Place the coated plate in an anaerobic box and culture at 37℃ for 24-48h. Select colonies with obvious differences and streak them on MRS solid medium, culture them anaerobically at 37℃ for 24-48h, and streak them 3-5 times continuously. Pick a single colony for hydrogen peroxide titration experiment. If the single colony picked produces bubbles on a slide dripped with 5% hydrogen peroxide solution, it is positive for catalase test. If no bubbles are produced, it is negative for catalase test. The negative strain is a suspected probiotic strain. The suspected probiotic strain ZJUF SYS1 was Gram-stained and the 16S rRNA gene was identified by Shanghai Paisonno Biological Co., Ltd. The base sequence of 16S rRNA of ZJUF SYS1 is shown in SEQ ID NO.1. Combined with biological characteristics and 16S rRNA gene comparison, ZJUF SYS1 was confirmed to be a strain of Lactobacillus plantarum and named Lactobacillus plantarum ZJUF SYS1. Lactobacillus plantarum ZJUF SYS1 was deposited in the China Center for Type Culture Collection (Address: Wuhan University, Wuhan, China) on May 18, 2022 with the accession number: CCTCC NO: M2022662, and was identified as alive on May 25, 2022.

[0042] Screening, isolation and identification of Lactobacillus rhamnosus ZJUF W1: 5 g Sichuan pickles were added to 45 mL 0.85% sterile saline and shaken well. The mixture was diluted to 10% with saline. -5 , 10 -6 , 10 -7 , respectively, spread on MRS medium, and make 3 parallels for each gradient. Place the coated plate in an anaerobic box and culture at 37℃ for 24-48h. Select colonies with obvious differences and streak them on MRS solid medium, culture them anaerobically at 37℃ for 24-48h, and streak them 3-5 times continuously. Pick a single colony for hydrogen peroxide titration experiment. If the single colony picked produces bubbles on a slide dripped with 5% hydrogen peroxide solution, it is positive for catalase test. If no bubbles are produced, it is negative for catalase test. The negative strain is a suspected probiotic strain. The suspected probiotic strain ZJUF W1 was Gram-stained and the 16S rRNA gene was identified. The identification was completed by Shanghai Paisonno Biological Co., Ltd. The base sequence of 16S rRNA of ZJUF W1 is shown in SEQ ID NO.2. After 16S rRNA gene comparison, ZJUF W1 was confirmed to be a strain of Lactobacillus rhamnosus and named Lactobacillus rhamnosus ZJUF W1. Lactobacillus rhamnosus ZJUF W1 was deposited in China Center for Type Culture Collection (Address: Wuhan University, Wuhan, China) on June 29, 2017 with the accession number: CCTCCNO:M 2017398, and was identified as alive on July 10, 2017.

[0043] Example 1: Evaluation of the constipation-relieving effect of probiotics in a mouse constipation model

[0044] 1. Preparation method of bacterial powder:

[0045] The activated Lactobacillus plantarum ZJUF T34, Lactobacillus plantarum ZJUF SYS1, and Lactobacillus rhamnosus ZJUFW1 were inoculated into sterile MRS liquid culture medium at 1% inoculation amount, cultured at 37°C for 24h, centrifuged at 5000rpm to obtain bacterial cells, and resuspended the bacterial cells with a sterilized mixed solution containing 5% skim milk powder and 5% lactose as a freeze-drying protective agent, and placed in a freeze dryer for freeze drying. Finally, the bacterial powder obtained after freeze drying was counted by pouring plate method.

[0046] A probiotic composition was prepared according to the bacterial contents of the three bacterial powders, and the contents of each bacteria in the composition were 1:1:1.

[0047] 2. Experimental feeding and grouping are as follows:

[0048] Seventy-two healthy male BALB / C mice aged 6 weeks were placed in an animal room and fed with a normal balanced diet for 7 days to adapt them to the experimental environment (12 h day / night). After the equilibrium period, the mice were randomly divided into 6 groups, including the normal group (CON, gavage with sterile saline for 16 days, twice a day, gavage with 10 mg / kg.bw of sterile saline from 10:00 a.m. every day, and gavage with 0.20 mL of sterile saline half an hour later), the model group (LOP, gavage with 10 mg / kg.bw of loperamide hydrochloride from 10:00 a.m. every day, once a day, and gavage with 0.20 mL of sterile saline half an hour later), the T34 group, the SYS1 group, the W1 group, and the mixed probiotics group (CP3) (gavage with 10 mg / kg.bw of loperamide hydrochloride from 10:00 a.m. every day, once a day, and gavage with 5×10 Lactobacillus plantarum T34, Lactobacillus plantarum ZJUF SYS1, Lactobacillus rhamnosus ZJFU W1, and mixed probiotics, 5×10 each) 10 CFU / mL, 0.20mL / time). The ratio of the three strains in CP3 was 1:1:1. Each group of mice had 12 mice, divided into 3 cages, 4 mice in each cage, in an environment (22±2℃), with a humidity of 30-70%, and mice were free to eat and drink water. The experiment lasted for 16 days.

[0049] 3. Effect on the time of first black stool in constipated mice

[0050] The mouse defecation experiment was conducted on the 14th day after gavage. The detection method is as follows: On the evening of the 13th day of the experiment, the mice were fasted but not watered for 16 hours. On the 14th day of the experiment, each group was gavaged with 0.1ml / 10g.bw (10mg / kg.bw) of loperamide hydrochloride capsules, and the blank control group was gavaged with the same volume of distilled water. 0.5h later, the blank group and the model control group were gavaged with ink, and the sample group was gavaged with ink solution containing corresponding contents, and the timing was started. The mice were placed in a metabolic cage and immediately resumed normal diet. Observe and record the time of the first black stool of each mouse, and the first black stool time of the last mouse in the model group was used as the termination time. The treatment group that exceeded the time of the first black stool of the model group was invalid.

[0051] The time of the first black stool of mice is a direct indicator of the speed of intestinal peristalsis. The faster the peristalsis, the shorter the time required for the first black stool of mice, and vice versa.

[0052] The experimental results are as follows Figure 1As shown in the figure, it can be seen that after loperamide hydrochloride modeling, the time of the first black stool of mice was significantly prolonged (p < 0.0001). After the intervention of the mixed probiotic combination, the time of the first black stool of mice was significantly reduced compared with the modeling group, and even had no significant difference with the normal group, that is, after the intervention of the mixed probiotics, the constipation of mice was relieved to normal levels. Compared with a single probiotic, the effect of the mixed probiotics is better than that of the single strains of each composition.

[0053] 4. Effect on the number of fecal particles in constipated mice within 5 hours

[0054] The number of fecal particles in mice within 5 hours was counted and statistically analyzed. The number of fecal particles is also an important indicator for evaluating mouse constipation. The more fecal particles there are, the lower the degree of constipation is generally.

[0055] The experimental results are as follows Figure 2 As shown in the results, after loperamide hydrochloride modeling, the number of fecal particles within 5 hours was significantly reduced compared with the normal group (p < 0.0001), and after probiotic combination intervention, it was significantly increased compared with the modeling group (LOP) (p < 0.0001). There was no significant difference between the probiotic combination intervention and the normal group (CON). Compared with single probiotics (T34, SYS1, W1), the constipation relief effect of the probiotic combination was stronger than that of a single probiotic.

[0056] 5. Effect on fecal water content in constipated mice

[0057] The fecal particles of mice within 5 hours were collected in time, stored with dry ice, and the wet weight of the mouse feces within 5 hours was weighed as M0. The mouse feces were dried to a constant weight and recorded as M1. The moisture content of mouse feces was (M0-M1) / M0×100%.

[0058] Constipation in mice is often accompanied by a decrease in fecal moisture content, which also slows down intestinal motility. Therefore, fecal moisture content is another important indicator for evaluating constipation in mice.

[0059] The results of the effect of the probiotic composition on the water content of feces of constipated mice are as follows Figure 3 As shown in the figure, after loperamide hydrochloride modeling, the fecal water content of mice was significantly reduced compared with the normal group, while after the intervention of the probiotic combination, the fecal water content returned to a level that was not significantly different from the normal group.

[0060] Example 2: Evaluation of the constipation-relieving effect of the probiotic and wheat peptide composition in a mouse constipation model

[0061] 1. Preparation of probiotics and wheat peptide composition

[0062] Lactobacillus plantarum ZJUF T34, deposit number is CCTCC NO:M 2017399, see Chinese patent application number 201711405499.4;

[0063] Lactobacillus plantarum ZJUF SYS1, accession number: CCTCC NO:M 2022662;

[0064] Lactobacillus rhamnosus ZJUF W1, the accession number is: CCTCC NO:M 2017398.

[0065] Wheat peptide is produced by Hangzhou Kangyuan Food Technology Co., Ltd.

[0066] The preparation method is:

[0067] The activated Lactobacillus plantarum ZJUF T34, Lactobacillus plantarum ZJUF SYS1, and Lactobacillus rhamnosus ZJUFW1 were inoculated into sterile MRS liquid culture medium at a rate of 1%, cultured at 37°C for 24 hours, centrifuged at 5000rpm to obtain the bacteria, and resuspended the bacteria with a sterilized mixed solution containing 5% skim milk powder and 5% lactose as a freeze-drying protective agent, and placed in a freeze dryer for freeze drying. Finally, the pour plate method was used to count the bacterial powder obtained after freeze drying. The probiotic composition was prepared according to the bacterial content of the three kinds of bacterial powders. The content of each bacteria in the composition was 1:1:1, and the bacterial content of each strain was 1×10 11 The mixed bacterial powder and wheat peptide were evenly mixed in a weight ratio of 1g:6g to prepare a combination powder of probiotics and wheat peptide.

[0068] 2. Experimental feeding and grouping are as follows:

[0069] Sixty healthy male BALB / C mice aged 6 weeks were placed in an animal room and fed with a normal diet for 7 days to adapt to the experimental environment (12h day / night). After the equilibrium period, they were randomly divided into 5 groups, namely the normal group (CON, gavage with sterile saline for 16 days, twice a day, gavage with sterile saline 10 mg / kg.bw starting at 10:00 every day, and gavage with sterile saline 0.20 mL / time half an hour later), the model group (LOP, gavage with loperamide hydrochloride 10 mg / kg.bw starting at 10:00 every day, once a day, and gavage with sterile saline 0.20 mL / time half an hour later), the probiotic group (CP3), the wheat peptide group (WP), and the probiotic and wheat peptide combination group (CP3+WP) [the three groups were gavaged with loperamide hydrochloride 10 mg / kg.bw starting at 10:00 every day, once a day, and gavage with three kinds of mixed probiotics (5.0×10 10CFU / mL, 0.20mL / time·animal), wheat peptide (100mg / mL, 0.20mL / time·animal), probiotics and wheat peptide ((5.0×10 10 CFU+100mg) / mL, 0.20mL / time / mouse)]. Each group of mice had 12 mice, which were divided into 3 cages with 4 mice in each cage, and the environment was (22±2°C) with a humidity of 30-70%.

[0070] 3. Effect of probiotics and wheat peptide combination on the time of first black stool in constipated mice

[0071] The mouse defecation experiment was conducted on the 14th day after gavage. The detection method is as follows: On the evening of the 13th day of the experiment, the mice were fasted but not watered for 16 hours. On the 14th day of the experiment, each group was gavaged with 0.1ml / 10g.bw (10mg / kg.bw) of loperamide hydrochloride capsules, and the blank control group was gavaged with the same volume of distilled water. 0.5h later, the blank group and the model control group were gavaged with ink, and the sample group was gavaged with ink solution containing corresponding contents, and the timing was started. The mice were placed in a metabolic cage and immediately resumed normal diet. Observe and record the time of the first black stool of each mouse, and the first black stool time of the last mouse in the model group was used as the termination time. The treatment group that exceeded the time of the first black stool of the model group was invalid.

[0072] The time of the first black stool of mice is a direct indicator of the speed of intestinal peristalsis. The faster the peristalsis, the shorter the time required for the first black stool of mice, and vice versa.

[0073] The experimental results are as follows Figure 4 As shown in the figure, it can be seen that after loperamide hydrochloride modeling, the time of the first black stool of mice was significantly prolonged (p < 0.0001). After the combined intervention of probiotics and wheat peptides, the time of the first black stool of mice was significantly reduced compared with the modeling group, and even had no significant difference with the normal group, that is, after the combined intervention of probiotics and wheat peptides, the constipation of mice was relieved to normal levels. Compared with the mixed probiotics and wheat peptides, the improvement effect was improved, indicating that probiotics and wheat peptides have a synergistic effect in relieving constipation.

[0074] 4. Effect of probiotics and wheat peptide combination on the number of fecal particles in constipated mice within 5 hours

[0075] The number of fecal particles in mice within 5 hours was counted and statistically analyzed. The number of fecal particles is also an important indicator for evaluating mouse constipation. The more fecal particles there are, the lower the degree of constipation is generally.

[0076] The experimental results are as follows Figure 5As shown in the results, after loperamide hydrochloride modeling, the number of fecal particles within 5 hours was significantly reduced compared with the normal group (p < 0.0001), and after probiotic combination intervention, it was significantly increased compared with the modeling group (LOP) (p < 0.0001). There was no significant difference between the probiotic combination intervention and the normal group (CON). Compared with mixed probiotics and wheat peptides, the constipation relief effect of the probiotics and wheat peptides combination was stronger than that of the single probiotic combination and single wheat peptide.

[0077] 5. Effect of probiotics and wheat peptide combination on fecal water content in constipated mice

[0078] The fecal particles of mice within 5 hours were collected in time, stored with dry ice, and the wet weight of the mouse feces within 5 hours was weighed as M0. The mouse feces were dried to a constant weight and recorded as M1. The moisture content of mouse feces was (M0-M1) / M0×100%.

[0079] Constipation in mice is often accompanied by a decrease in fecal moisture content, which also slows down intestinal motility. Therefore, fecal moisture content is another important indicator for evaluating constipation in mice.

[0080] The results of the effect of the probiotic composition on the water content of feces of constipated mice are as follows Figure 6 As shown in the figure, after loperamide hydrochloride modeling, the fecal water content of mice was significantly reduced compared with the normal group, while after the combined intervention of probiotics and wheat peptides, the fecal water content returned to a level that was not significantly different from the normal group, indicating that the combination can effectively increase the water content of feces and promote the relief and treatment of constipation.

[0081] Example 3: Evaluation of constipation-relieving effects of probiotic compositions with different ratios using a zebrafish constipation model

[0082] This example uses a constipation zebrafish model to evaluate the ability of different ratios of probiotic compositions to relieve constipation. The genetic similarity between zebrafish and humans is as high as 87%, and the intestines are also very similar to humans. This experiment uses loperamide hydrochloride to create a model.

[0083] The zebrafish embryos after 12 hours of development were transferred to a 6-well plate with a pipette, and 20 zebrafish embryos and 6 mL of embryo culture medium containing phenylthiourea (10 μL of phenylthiourea mother solution was contained in each 1 mL of embryo culture medium) were added to each well. 3 mL of the newly prepared mixture of phenylthiourea and embryo culture medium was replaced every other day, and cultured for 2 days. After the zebrafish developed to the 5th day, the mixture of phenylthiourea and embryo culture medium in each well was removed, and 6 mL of the test sample of different concentrations was added to each experimental group, among which the control group (CON) was a blank control, and E3 zebrafish culture system water was added, and 10 ug / mL loperamide hydrochloride (Lop) was added to the model group (LOP), and the experimental group T34:SYS1:W1=10:1:1 was 10 ug / mL Lop and the combination (10 / 12×10 8 CFU / mL T34+1 / 12×10 8 CFU / mL SYS1+1 / 12×10 8 CFU / mL W1), experimental group T34:SYS1:W1=1:10:1 is 10ug / mL Lop and composition (1 / 12×10 8 CFU / mL T34+10 / 12×10 8 CFU / mL SYS1+1 / 12×10 8 CFU / mL W1), experimental group T34:SYS1:W1=1:1:10, 10ug / mL Lop and composition (1 / 12×10 8 CFU / mL T34+1 / 12×10 8 CFU / mL SYS1+10 / 12×10 8 CFU / mL W1), experimental group T34:SYS1:W1=10:5:1 was 10ug / mL Lop and the composition (10 / 16×10 8 CFU / mL T34+5 / 16×10 8 CFU / mL SYS1+1 / 16×10 8 CFU / mL W1), experimental group T34:SYS1:W1=5:10:1 was 10ug / mL Lop and the composition (5 / 16×10 8 CFU / mL T34+10 / 16×10 8 CFU / mL SYS1+1 / 16×10 8 CFU / mL W1), experimental group T34:SYS1:W1=1:5:10 is 10ug / mL Lop and composition (1 / 16×10 8 CFU / mL T34+5 / 16×10 8 CFU / mL SYS1+10 / 16×108 CFU / mL W1). Each group was paralleled to 3, and after 24 h of drug treatment, the intestinal peristalsis of zebrafish was recorded using a microscope video.

[0084] The observations were recorded under a microscope, and the time required between two peristaltic peaks corresponding to the fourth segment of the zebrafish posterior vesicle (called the time of the first peristaltic peak) was recorded. The differences in zebrafish intestinal peristalsis speed between different drug treatment groups and the blank control group and modeling group were compared.

[0085] The experimental results are as follows Figure 7 As shown, the results of the zebrafish model showed that after modeling with loperamide hydrochloride, the first peristaltic peak of the zebrafish intestine was significantly slowed down compared with the blank control, and probiotic compositions with different ratios could significantly accelerate intestinal peristalsis.

Claims

1. A probiotic composition for relieving constipation, It is characterized in that The probiotic composition comprises a probiotic combination, which comprises: Lactobacillus plantarum ZJUF SYS1 with a preservation number of CCTCC NO: M 2022662, Lactobacillus plantarum ZJUF T34 with a preservation number of CCTCC NO: M 2017399 and Lactobacillus rhamnosus ZJUF W1 with a preservation number of CCTCC NO: M 2017398, wherein the colony count ratio of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUFW1 in the composition is 1-10:1-10:1-10.

2. The probiotic composition for relieving constipation according to claim 1, It is characterized in that The colony count per unit mass of Lactobacillus plantarum ZJUF SYS1, Lactobacillus plantarum ZJUF T34 and Lactobacillus rhamnosus ZJUF W1 in the composition is 1×10 5 ~1×10 12 CFU / g.

3. The probiotic composition for relieving constipation according to claim 1, It is characterized in that The invention also comprises auxiliary ingredients, wherein the auxiliary ingredients include wheat peptides, and the wheat peptides are glutenin enzymatic hydrolysates.

4. The probiotic composition for relieving constipation according to claim 3, It is characterized in that The hydrolysis degree of the wheat peptide is 5.0-8.0%, wherein the peptide with a relative molecular weight less than 1000Da accounts for 45-60%.

5. The probiotic composition for relieving constipation according to claim 3 or 4, It is characterized in that The ratio of probiotic combination and auxiliary ingredients in the composition is 1×10 5 CFU~1×10 12 CFU: 1~6g.

6. The probiotic composition for relieving constipation according to claim 5, It is characterized in that The ratio of probiotic combination and wheat peptide in the composition is 1×10 10 CFU~1×10 12 CFU: 1~6g.

7. Use of the probiotic composition according to any one of claims 1 to 6 in the preparation of a medicine for treating or assisting in the treatment of constipation or a food for alleviating constipation.

8. The use according to claim 7, It is characterized in that The constipation is functional constipation.

Citation Information

Patent Citations

  • Lactobacillus plantarum ZJUF T34 and application thereof

    CN109234182A

  • Wheat peptide as well as preparation method and application thereof

    CN112226478A

  • Lactobacillus rhamnosus LR519 capable of alleviating constipation, and composition of lactobacillus rhamnosus LR519

    CN112237287A

  • Composition with function of relieving constipation and preparation method thereof

    CN114831286A

  • Lactobacillus plantarum ZJUF SYS1 and application thereof

    CN115960784A

Cited By

  • Application of compound probiotic feed additive in preparation of feed for improving earthy smell of cultured largemouth bass

    CN118355959A